Loading…
Senti Biosciences Holdings, Inc. is projected to decline to $0.978 by 2027, a -3% move from its current price of $1.01. SNTI is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.9657 | $1.01 | $1.06 | -0.04% |
| May 30 | $0.9477 | $1.01 | $1.07 | -0.09% |
| May 31 | $0.934 | $1.01 | $1.09 | -0.13% |
| Jun 1 | $0.9226 | $1.01 | $1.10 | -0.17% |
| Jun 2 | $0.9126 | $1.01 | $1.11 | -0.22% |
| Jun 3 | $0.9036 | $1.01 | $1.12 | -0.26% |
| Jun 4 | $0.8953 | $1.01 | $1.13 | -0.30% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8953 | $1.01 | $1.13 | -0.30% |
| Week 2 | $0.8502 | $1.00 | $1.19 | -0.60% |
| Week 3 | $0.8166 | $1.00 | $1.23 | -0.90% |
| Week 4 | $0.7889 | $0.9979 | $1.26 | -1.20% |
| Week 5 | $0.765 | $0.9949 | $1.29 | -1.50% |
| Week 6 | $0.7438 | $0.9918 | $1.32 | -1.80% |
| Week 7 | $0.7247 | $0.9889 | $1.35 | -2.09% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Senti Biosciences Holdings, Inc. is a healthcare company operating in the clinical stage biotechnology space. It develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.
Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
The company offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. Its pipeline also includes preclinical programs and partnered programs related to cell therapies for regenerative medicines. Senti Biosciences was incorporated in 2016, is headquartered in South San Francisco, California, and changed its name to Senti Biosciences Holdings, Inc.
in April 2026. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd.
SNTI trades as a healthcare stock with a current price of $0.9869 and a market capitalization of $30.74M. It is ranked 4794 by market cap among listed equities.
The 30-day price range runs from $0.7242 to $1.34, reflecting recent trading activity and volatility. The stock’s technical backdrop shows a NEUTRAL stance, with a 50-reading on the RSI and notable levels for short-term support and resistance.
Looking ahead, the forecast suggests a mixed near term, followed by a shift toward bullish momentum in the later years. The average price is projected to rise from the mid-to-lower levels in 2026 through a higher trajectory by 2050, with long-term upside implied by the projected averages and ROIs.
A major floor 25.7% below — a decisive break under it would weaken the trend.
The nearest floor, 12.9% below — buyers have tended to step in here.
The nearest ceiling, 12.9% above — a clean break opens room to run.
A major ceiling 25.7% above — clearing it would confirm fresh momentum.
Key SNTI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SNTI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.9906 | Buy | $0.9898 | Buy |
| MA 10 | $0.9786 | Buy | $0.9836 | Buy |
| MA 20 | $0.9772 | Buy | $0.9811 | Buy |
| MA 50 | $0.9518 | Buy | $0.981 | Buy |
| MA 100 | $0.9694 | Buy | $1.08 | Sell |
| MA 200 | $1.31 | Sell | $1.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.18 | Neutral |
| Stoch RSI (14) | 83.41 | Sell |
| CCI (20) | 80.51 | Neutral |
| Williams %R (14) | -18.75 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 2.43 | Buy |
| Bollinger %B (20,2) | 0.73 | Neutral |
| Stochastic %K (14) | 81.25 | Sell |
| TRIX (15) | 0.07 | Buy |
| Awesome (5,34) | 0.00 | Buy |
| Ultimate (7,14,28) | 51.43 | Neutral |
| Momentum (10) | 0.04 | Buy |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 1.00 | Buy |
| ADX (14) | 7.59 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL with RSI(14) at 50. The 50-day simple moving average is $0.95 and the 200-day simple moving average is $1.32. Key near-term support sits at $0.88 and resistance at $1.14.
The 30-day price range spans from a low of $0.7242 to a high of $1.34, indicating a relatively tight trading band. Annualized volatility is high at 90%, underscoring substantial price movement potential within the broader range.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.772 | $1.01 | $1.29 | 0% | Neutral | |
| $0.7285 | $0.978 | $1.41 | -3% | Neutral | |
| $0.7009 | $0.9866 | $1.50 | -2% | Neutral | |
| $0.8348 | $1.22 | $1.94 | +21% | Bullish | |
| $1.02 | $1.54 | $2.54 | +53% | Bullish | |
| $0.8845 | $1.39 | $2.36 | +38% | Bullish | |
| $0.8628 | $1.40 | $2.44 | +39% | Bullish | |
| $0.9095 | $1.52 | $2.72 | +51% | Bullish | |
| $0.7365 | $1.27 | $2.32 | +26% | Bullish | |
| $0.841 | $1.49 | $2.78 | +48% | Bullish | |
| $0.9106 | $1.85 | $3.75 | +83% | Bullish | |
| $1.95 | $4.33 | $9.89 | +329% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.772 | $1.01 | $1.20 | +0.00% |
| June 2026 | $0.8585 | $1.02 | $1.26 | +1.20% |
| July 2026 | $0.8043 | $0.971 | $1.22 | -5.00% |
| August 2026 | $0.792 | $0.9667 | $1.23 | -0.44% |
| September 2026 | $0.8265 | $1.02 | $1.32 | +5.30% |
| October 2026 | $0.8095 | $1.01 | $1.32 | -1.23% |
| November 2026 | $0.7607 | $0.9518 | $1.26 | -5.33% |
| December 2026 | $0.7652 | $0.9643 | $1.29 | +1.31% |
Click any year to see its month-by-month SNTI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The SNTI price prediction for 2026 points to an average of $1.01 (low $0.772, high $1.29) — a potential gain of 0% on today's $1.01. A consolidation phase looks the most probable path here.
In 2027, SNTI is projected to trade between $0.7285 and $1.41, averaging $0.978 — a potential decline of -3% from today's $1.01. That is -3% versus the projected 2026 average. Price action looks broadly range-bound.
Senti Biosciences Holdings, Inc.'s 2028 outlook centres on $0.9866, within a $0.7009 to $1.50 range. That is up +1% on the projected 2027 average. That marks a -2% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, SNTI could reach as high as $1.94, with a base case around $1.22 and support toward $0.8348 — roughly +21% from $1.01. Momentum favours further upside here.
Expect SNTI to range from $1.02 to $2.54 through 2030. The $1.54 average target implies a +53% move from current prices. That is up +26% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The SNTI price prediction for 2031 points to an average of $1.39 (low $0.8845, high $2.36) — a potential gain of +38% on today's $1.01. Momentum favours further upside here.
In 2032, SNTI is projected to trade between $0.8628 and $2.44, averaging $1.40 — a potential gain of +39% from today's $1.01. That is up +1% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Senti Biosciences Holdings, Inc.'s 2033 outlook centres on $1.52, within a $0.9095 to $2.72 range. That is up +9% on the projected 2032 average. That marks a +51% change versus current levels. Momentum favours further upside here.
By 2034, SNTI could reach as high as $2.32, with a base case around $1.27 and support toward $0.7365 — roughly +26% from $1.01. Buyers look set to stay in control over this stretch.
Expect SNTI to range from $0.841 to $2.78 through 2035. The $1.49 average target implies a +48% move from current prices. That is up +18% on the projected 2034 average. Momentum favours further upside here.
The SNTI price prediction for 2040 points to an average of $1.85 (low $0.9106, high $3.75) — a potential gain of +83% on today's $1.01. Buyers look set to stay in control over this stretch.
In 2050, SNTI is projected to trade between $1.95 and $9.89, averaging $4.33 — a potential gain of +329% from today's $1.01. That is up +134% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SNTI today (≈ 990.09901 SNTI) could be worth
$4,291.43
+$3,291.43 (+329%) by 2050 · US Dollar
Based on the average projected SNTI price of $4.33 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SNTIwould be worth at today's price.
$1,000 invested in SNTI on May 27, 2025 (≈ 302.114809 SNTI) would be worth
$305.14
-$694.86 (-69.5%) today · 0.31× · US Dollar
Based on a SNTI entry price of $3.31 vs. today's $1.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.98 | $1,030.61 | +3.1% |
| 1 month ago | $1.06 | $952.83 | -4.7% |
| 3 months ago | $0.981 | $1,029.56 | +3.0% |
| 6 months ago | $2.23 | $452.91 | -54.7% |
| 1 year ago | $3.31 | $305.14 | -69.5% |
| All time (5.0y) ago | $99.9 | $10.11 | -99.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SNTI forecast.
Our base-case forecast reaches $2.00 around 2050.
Implied market cap at $2.00: $62.29M
The multi-year forecast shows the average price rising over time with varied returns across years. For 2026 the average is $0.9869 with a 0% ROI, followed by 2027 at $0.9356 with a -5.2% ROI and 2028 at $0.9475 with a -4% ROI. In 2029 the average climbs to $1.19 with a 20.8% ROI, and 2030 reaches $1.49 with a 51.4% ROI, signaling a bullish shift.
From 2031 onward, the forecast remains bullish with 2031 at $1.34 (36%), 2032 at $1.36 (38.2%), 2033 at $1.46 (48.1%), 2034 at $1.20 (21.2%), and 2035 at $1.43 (44.9%). The long-range horizon strengthens further with 2040 at $1.75 (77.4%) and 2050 at $4.18 (323.3%). These figures point to meaningful upside by 2050, albeit with earlier years showing softer or negative returns.
These are estimates and not guarantees, and actual results may differ due to market and company-specific factors.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $1.49, with a maximum of $2.50 and a minimum of $0.9638. The expected ROI for 2030 is 51.4%.
The forecast shows a bullish view starting in 2029 with an average around $1.19 in 2029 and $1.49 in 2030, rising to a long-run average of $4.18 by 2050 and an ROI of 323.3%. Earlier years include neutral or negative ROI, so outcomes are uncertain and not guarantees.
Yes. The forecast lists a maximum of $2.50 in 2030, indicating the potential to reach that level within the projection.
The 30-day range is from $0.7242 to $1.34.
Current price is $0.9869 and market cap is $30.74M, with a rank of 4794.
Senti Biosciences Holdings, Inc. Community Discussion
0Share your Senti Biosciences Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.